EA200700391A1 - COMBINED TREATMENT WITH THE APPLICATION OF TRANSFERRIN SLIP PROTEINS CONTAINING GLP-1 - Google Patents
COMBINED TREATMENT WITH THE APPLICATION OF TRANSFERRIN SLIP PROTEINS CONTAINING GLP-1Info
- Publication number
- EA200700391A1 EA200700391A1 EA200700391A EA200700391A EA200700391A1 EA 200700391 A1 EA200700391 A1 EA 200700391A1 EA 200700391 A EA200700391 A EA 200700391A EA 200700391 A EA200700391 A EA 200700391A EA 200700391 A1 EA200700391 A1 EA 200700391A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- transferrin
- slip
- application
- combined treatment
- proteins containing
- Prior art date
Links
- 102000004338 Transferrin Human genes 0.000 title abstract 3
- 108090000901 Transferrin Proteins 0.000 title abstract 3
- 239000012581 transferrin Substances 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Optics & Photonics (AREA)
- Food Science & Technology (AREA)
Abstract
Настоящее изобретение относится к комбинированному лечению, включающему в себя слитый белок трансферрина и ингибиторы DPP-IV и/или ингибиторы нейтральной пептидазы (NEP). Слитый белок трансферрина содержит терапевтические полипептиды или пептиды, пригодные для лечения таких заболеваний, как диабет.The present invention relates to a combination treatment comprising a transferrin fusion protein and DPP-IV inhibitors and / or neutral peptidase inhibitors (NEP). Transferrin fusion protein contains therapeutic polypeptides or peptides suitable for the treatment of diseases such as diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59803104P | 2004-08-03 | 2004-08-03 | |
PCT/US2005/027800 WO2006017688A2 (en) | 2004-08-03 | 2005-08-03 | Combination therapy using transferrin fusion proteins comprising glp-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200700391A1 true EA200700391A1 (en) | 2007-10-26 |
Family
ID=35839920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200700391A EA200700391A1 (en) | 2004-08-03 | 2005-08-03 | COMBINED TREATMENT WITH THE APPLICATION OF TRANSFERRIN SLIP PROTEINS CONTAINING GLP-1 |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1814599A4 (en) |
JP (1) | JP2008509153A (en) |
KR (1) | KR20070085224A (en) |
CN (1) | CN101035568A (en) |
AP (1) | AP2007003920A0 (en) |
AU (1) | AU2005271403A1 (en) |
BR (1) | BRPI0514115A (en) |
CA (1) | CA2575756A1 (en) |
CR (1) | CR8954A (en) |
EA (1) | EA200700391A1 (en) |
GB (1) | GB2431583A (en) |
IL (1) | IL181108A0 (en) |
MA (1) | MA28843B1 (en) |
MX (1) | MX2007001424A (en) |
NO (1) | NO20071018L (en) |
RU (1) | RU2007107808A (en) |
TN (1) | TNSN07039A1 (en) |
WO (1) | WO2006017688A2 (en) |
ZA (1) | ZA200701484B (en) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
DE60318938T2 (en) | 2002-03-20 | 2009-01-22 | Mannkind Corp., Valencia | INHALER |
ES2385934T3 (en) | 2004-08-20 | 2012-08-03 | Mannkind Corporation | CATALYSIS OF THE SYNTHESIS OF DICETOPIPERAZINA. |
EP2314298B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Microparticles comprising diketopiperazine salts for drug delivery |
CA2599723A1 (en) * | 2005-03-04 | 2006-09-14 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
KR20160022404A (en) | 2005-09-14 | 2016-02-29 | 맨카인드 코포레이션 | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
MX2008010721A (en) | 2006-02-22 | 2008-09-01 | Mannkind Corp | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent. |
CN101432025B (en) | 2006-03-21 | 2012-04-04 | 安米林药品公司 | Peptide-peptidase inhibitor conjugates and methods of using same |
CN101511868B (en) | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | Exendin fusion proteins |
WO2008033395A2 (en) * | 2006-09-14 | 2008-03-20 | Biorexis Pharmaceutical Corporation | Melanocortin and transferrin fusion proteins |
EP2195034A2 (en) | 2007-09-27 | 2010-06-16 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
EP3281663B8 (en) | 2008-06-13 | 2022-09-21 | MannKind Corporation | Breath powered dry powder inhaler for drug delivery |
MX2010014240A (en) | 2008-06-20 | 2011-03-25 | Mankind Corp | An interactive apparatus and method for real-time profiling of inhalation efforts. |
TWI614024B (en) | 2008-08-11 | 2018-02-11 | 曼凱公司 | Use of ultrarapid acting insulin |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US8551528B2 (en) | 2009-06-12 | 2013-10-08 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
BR112012033060A2 (en) | 2010-06-21 | 2018-02-27 | Mannkind Corp | Dry powder drug release system methods |
EP2610619B1 (en) * | 2010-08-27 | 2020-01-08 | University of Miyazaki | Hemokinin-1 receptor and hemokinin-1-derived peptide |
KR101940832B1 (en) | 2011-04-01 | 2019-01-21 | 맨카인드 코포레이션 | Blister package for pharmaceutical cartridges |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
RU2477726C1 (en) * | 2011-10-18 | 2013-03-20 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | Substituted phenoxyacetic acids, their esters and amides containing 2,6-dioxo-2,3,6,7-tetrahydro-1h-pyrin-8-yl fragments - a2a adenosine receptor antagonists and use thereof |
EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
CN103160565A (en) * | 2011-12-09 | 2013-06-19 | 彩虹天健康科技研究(北京)有限责任公司 | Research for influence on endocytosis of cell transferrins of UNC-51 kinase |
US9809641B2 (en) | 2012-04-23 | 2017-11-07 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
JP2016503771A (en) | 2012-12-21 | 2016-02-08 | サノフイ | Exendin-4 derivative |
EP3587404B1 (en) | 2013-03-15 | 2022-07-13 | MannKind Corporation | Microcrystalline diketopiperazine compositions, methods for preparation and use thereof |
CN103275177B (en) * | 2013-06-24 | 2015-08-12 | 南京财经大学 | There is the little peptide of feritin and ACE dual restraining activities, its preparation method and application |
BR122019026637B1 (en) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | PHARMACEUTICAL DRY POWDER FORMULATIONS AND METHOD FOR MANUFACTURING A DRY POWDER FORMULATION |
CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609796A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Non-acylated EXENDIN-4 peptide analogues |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
CN104645317B (en) * | 2015-01-28 | 2020-04-17 | 中国科学院天津工业生物技术研究所 | Application of polypeptide compound as polypeptide or protein drug carrier, method and fusion protein compound thereof |
AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
AR105284A1 (en) | 2015-07-10 | 2017-09-20 | Sanofi Sa | DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS |
CN110114460A (en) | 2016-10-28 | 2019-08-09 | Nrl制药股份有限公司 | Lactoferrin/albumin fusion protein matter and preparation method thereof |
US11459368B2 (en) | 2017-07-14 | 2022-10-04 | Livactus, Inc. | Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance |
ES2929416T3 (en) * | 2018-06-21 | 2022-11-29 | Novo Nordisk As | New compounds for the treatment of obesity |
CN110218259B (en) * | 2019-06-24 | 2022-09-16 | 王跃驹 | Application of fusion protein of glucagon-like peptide-1 short peptide and transferrin produced by plants in preparing oral hypoglycemic capsules |
CN112661862B (en) * | 2020-12-25 | 2023-03-31 | 深圳大学 | Fusion protein and preparation method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US7285526B2 (en) * | 1995-07-14 | 2007-10-23 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
PT1317479E (en) * | 2000-09-06 | 2009-10-29 | Univ Pasteur | Methods and compositions for diseases associated with amyloidosis |
US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
WO2004019872A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Oral delivery of modified transferrin fusion proteins |
WO2003057200A2 (en) * | 2002-01-11 | 2003-07-17 | Novo Nordisk A/S | Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
CN102268094A (en) * | 2002-08-30 | 2011-12-07 | 比奥雷克西斯药物公司 | Modified transferrin fusion proteins |
-
2005
- 2005-08-03 JP JP2007525008A patent/JP2008509153A/en not_active Withdrawn
- 2005-08-03 EP EP05782173A patent/EP1814599A4/en not_active Withdrawn
- 2005-08-03 MX MX2007001424A patent/MX2007001424A/en not_active Application Discontinuation
- 2005-08-03 BR BRPI0514115-0A patent/BRPI0514115A/en not_active IP Right Cessation
- 2005-08-03 CN CNA2005800336740A patent/CN101035568A/en active Pending
- 2005-08-03 KR KR1020077005257A patent/KR20070085224A/en not_active Application Discontinuation
- 2005-08-03 ZA ZA200701484A patent/ZA200701484B/en unknown
- 2005-08-03 CA CA002575756A patent/CA2575756A1/en not_active Abandoned
- 2005-08-03 AU AU2005271403A patent/AU2005271403A1/en not_active Abandoned
- 2005-08-03 AP AP2007003920A patent/AP2007003920A0/en unknown
- 2005-08-03 WO PCT/US2005/027800 patent/WO2006017688A2/en active Application Filing
- 2005-08-03 EA EA200700391A patent/EA200700391A1/en unknown
- 2005-08-03 RU RU2007107808/14A patent/RU2007107808A/en not_active Application Discontinuation
-
2007
- 2007-02-01 IL IL181108A patent/IL181108A0/en unknown
- 2007-02-02 TN TNP2007000039A patent/TNSN07039A1/en unknown
- 2007-02-22 NO NO20071018A patent/NO20071018L/en not_active Application Discontinuation
- 2007-02-26 GB GB0703685A patent/GB2431583A/en not_active Withdrawn
- 2007-03-02 MA MA29727A patent/MA28843B1/en unknown
- 2007-03-02 CR CR8954A patent/CR8954A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2008509153A (en) | 2008-03-27 |
IL181108A0 (en) | 2007-07-04 |
WO2006017688A2 (en) | 2006-02-16 |
CA2575756A1 (en) | 2006-02-16 |
GB0703685D0 (en) | 2007-04-04 |
AU2005271403A1 (en) | 2006-02-16 |
CN101035568A (en) | 2007-09-12 |
MX2007001424A (en) | 2008-03-13 |
EP1814599A4 (en) | 2008-12-17 |
RU2007107808A (en) | 2008-09-10 |
AP2007003920A0 (en) | 2007-02-28 |
MA28843B1 (en) | 2007-09-03 |
WO2006017688A3 (en) | 2006-08-03 |
TNSN07039A1 (en) | 2008-06-02 |
EP1814599A2 (en) | 2007-08-08 |
KR20070085224A (en) | 2007-08-27 |
ZA200701484B (en) | 2008-07-30 |
CR8954A (en) | 2007-10-02 |
NO20071018L (en) | 2007-04-11 |
BRPI0514115A (en) | 2008-05-27 |
GB2431583A (en) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200700391A1 (en) | COMBINED TREATMENT WITH THE APPLICATION OF TRANSFERRIN SLIP PROTEINS CONTAINING GLP-1 | |
EA200702208A1 (en) | DIPEPTIDYLPEPTIDASE-IV INHIBITORS | |
DK1692158T3 (en) | VEGF binding and supported peptides for the treatment of skin diseases | |
WO2009147248A3 (en) | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases | |
EA201290722A1 (en) | RECOMBINANT PROTEIN EXENDIN-4 AND ITS ANALOGUE, METHOD OF THEIR PREPARATION AND USE | |
GEP20105111B (en) | Rage fusion proteins and methods of use | |
EA201100070A1 (en) | RV2386C TUBERCULOSIC PROTEIN, COMPOSITIONS AND THEIR APPLICATIONS | |
EA200600869A1 (en) | ANTIBODIES CONNECTING INTERLEUKIN-4 RECEPTOR | |
UA107330C2 (en) | Tuberculous protein rv3616c and its application | |
ATE525395T1 (en) | FUSION PROTEINS OF GLP-1 ANALOGS | |
IS7753A (en) | Beta-amino heterocyclic dipeptidyl peptidase inhibits the treatment of, or prevention of diabetes mellitus | |
ME00185B (en) | Specific binding agents of human angiopoietin-2 | |
DE60330767D1 (en) | FERRITINFUSION PROTEINS FOR USE IN VACCINES AND OTHER APPLICATIONS | |
MX2009002999A (en) | Protease resistant insulin analogues. | |
ECSP088962A (en) | NEW HERBICIDES | |
ATE473742T1 (en) | CONDENSED TRIAZOLE DERIVATIVES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR TREATMENT OR PREVENTION OF DIABETES | |
WO2008121615A3 (en) | Antibody formulation | |
GEP20115324B (en) | Tweak binding antibodies | |
EA201100071A1 (en) | NEW COMPOSITIONS AND METHODS | |
MX2010002716A (en) | Neuroendocrine factors for treatment of degenerative diseases. | |
EA200600735A1 (en) | NUCLEIC ACIDS, SPECIFICALLY BINDING BIOACTIVE GREELINE | |
IL189452A0 (en) | Therapy with cd4 binding peptides and radiation | |
CY1109631T1 (en) | USE OF PEPTIDES, WHICH HAVE BEEN PRODUCED BY AA- OR BB-CHAIN OF HUMAN INODOGENE, FOR SOK THERAPY | |
WO2005059131A3 (en) | Protein binding miniature proteins and uses thereof | |
EA200501711A1 (en) | FAMILY OF SECRETABLE PROTEINS |